ASCO 2019 – Caring for every patient, learning from every patient (August 2019 – Article)

Participate in the Lung Cancer Registry, a community powered by patients and the patient voice. Together, moving lung cancer developments forward.

Last month, some of the greatest minds in cancer research got together at one of the biggest annual cancer conferences, American Society of Clinical Oncology (ASCO). GO₂ Foundation attended, below are some exciting highlights:

  • ACA Medicaid reduces disparities in cancer care | Previously reported racial disparities in receiving timely cancer treatment has almost completely vanished in states where access to Medicaid was expanded under the Affordable Care Act (ACA). *
  • 1 in 4 NSCLC patients alive at 5 years after pembrolizumab (Keytruda) | Data from the longest-running safety and follow up study suggests “pembrolizumab has the potential to improve long-term outcomes for both treatment-naive and previously treated patients with advanced non-small cell lung cancer (NSCLC).” These outcomes are particularly significant for patients with a high PD-L1 expression. *
  • Less toxicity with proton beam vs. photon chemoradiotherapy | Non-metastatic lung cancer patients are 69% less likely to have toxic events requiring hospitalization while on proton beam therapy. Although proton beam and photon chemoradiotherapy have similar survival outcomes, proton beam therapy has significantly fewer adverse events.*

If you’d like to read more from the conference, follow these links:

Thank you for your time and ongoing support of the Lung Cancer Registry. Your participation and willingness to share your health history will improve your own life as well as the lives of many others.

Together we can make a difference as we continue the fight to end lung cancer.

Sandra Shaw
Director, Patient Registry
GO₂ Foundation for Lung Cancer
This email address is being protected from spambots. You need JavaScript enabled to view it.

*Source: Medscape 2019 ASCO Slideshow